Get the Latest Investment Ideas Delivered Straight to Your Inbox.

TICKERS: GAIA

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months
Contributed Opinion

Source:

Peter Epstein Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange.

Gaia Grow Corp. (GAIA:TSX.V) (formerly Spirit Bear Capital) announced that effective August 1, its shares will be trading on the TSX Venture Exchange. Shares outstanding = 200.2 million. A July, 2019 capital raise was completed at $0.10, market cap = $20.2 million. (Note: ~124.7 million [~62%] of outstanding shares are locked up under various escrow agreements). This company comes by way of a Reverse Take Over (RTO).

Investors should review all applicable SEDAR filings and company press releases before investing in a RTO.

Peter Epstein & Epstein Research [ER], together [ER], have no former or existing relationship with any person or company mentioned below. However, at the time this interview was posted, [ER] was negotiating to secure Gaia Grow as an advertising client. While Gaia is not an advertiser on [ER] as of August 1, 2019, please consider [ER] biased in favor of the company. As of Aug. 1, Peter Epstein owned no shares, options or warrants in Gaia, or its predecessor company, but he may acquire shares in the open market.

Quick, name the top 3 #hemp / #CBD players…

By now most investors know that there are [#cannabis / dispensary] stocks, and [#hemp / #CBD] stocks. Cannabis stocks include Licensed Producers (LPs) like Canopy Growth and Aurora Cannabis, and Multiple State Operators (MSOs)—that sell cannabis through dispensaries in the U.S.—companies like Curaleaf and Green Thumb Industries. A MSO is the U.S. version of a Canadian LP.

Then we have the hemp / CBD players…. wait, where are my hemp and CBD names? Ahh, oh, here we go, Charlotte's Web, # 9 of the top 50 …. and next is …. silence. Unless one accepts processing companies like Medipharm, who primarily extract CBD from acquired hemp, there's only one large publicly traded hemp cultivation company on the planet!

Addressable market, stupid

Cannabis companies outnumber hemp-focused names by 10 or 12 to 1, implying that demand and acceptance of cannabis by users and various legal and political entities must be very high. Yet this simply is not the case. Cannabis is still a tough sell in most of the world.

Think about the global market for CBD (with < 0.3% THC). What percentage of adults might use CBD in its many forms for preventative health measures, specific aliments, or health and wellness? I estimate 60%–75% could be consuming CBD regularly, or at least occasionally. By contrast, cannabis (with > 1% THC) is used in only two ways, recreationally and medically.

What percentage of adults might use cannabis? I estimate just 15%–30%. Zero % of children, Zero % of pets. Finally, CBD is legally available in far more countries and jurisdictions than cannabis. Therefore, in my opinion, CBD demand next decade could be > 5x that of medical and recreational cannabis combined.

With that in mind, I interviewed Frederick Pels, CEO, chairman & co-founder of Gaia Grow Corp. (TSX-V: GAIA). Fredrick is very active in the cannabis / hemp space in Canada. He and his partners were early champions of medical cannabis, successfully advocating for its wider use and acceptance.

His prior company, the Green Room, was a leader in medical cannabis supply, industry best practices and education. The Green Room helped form, and get passed, many of the rules and regulations that make medical cannabis safe, affordable and accessible today. Fredrick and his team made valuable connections with people and companies in agriculture, finance, legal / compliance, cannabis, hemp, extraction and related sectors. The following interview was conducted by phone & email from July 26 to July 31st. {corporate website}

Peter Epstein: Fredrick, thank you for your time. Please give readers the latest snapshot of Gaia Grow Corp.

Frederick Pels: Sure. We have a strong management team and board, supportive shareholders, deep roots in the community and tremendous contacts in agriculture, finance and banking. We have vast experience in the Canadian cannabis and hemp space dating back more than 5 years. We understand how to navigate the increasing number of rules & regulations that cannabis & hemp growers face, because in many cases we helped develop them!

Most important, although there are other hemp / cannabis assets and opportunities held by Gaia Grow, our only active operation is a 1,494-acre crop of hemp plants that are about a month old and a half foot (15 cm) tall. Harvest is expected at the end of September or early October.

Peter Epstein: Can you tell us about co-founder James Tworek?

Frederick Pels: Yes, of course. James is a director and co-founder. He has a strong background, over 20 years' experience, in banking and finance. He was a partner at a mortgage brokerage and then in a commercial development fund. In 2016, James worked on corporate finance contracts in the Canadian Medical Cannabis sector, giving him hands-on experience in early-stage development financing and capital raising.

Those roles make him well versed in corporate finance, mezzanine funding, equity-based lending and business start-ups. James' experience in raising capital has brought him success in structured finance (including global deals) and he has built strong business relationships with family offices, private equity and venture capital firms.

Peter Epstein: Your recent background and experience is in medical cannabis, yet Gaia Grow is actively pursuing hemp. Is hemp a better investment opportunity than cannabis?

Frederick Pels: First and foremost, I'm an entrepreneur, a business owner, so my aim is to satisfy an under-served or un-met need. To me, hemp seems better positioned than cannabis, but Gaia Grow is looking at various cannabis situations as well. We think the opportunities for a small company to grow very rapidly are much greater in the hemp space than in cannabis.

Peter Epstein: What can you tell us about Gaia Grow's hemp crop in southern Alberta?

Frederick Pels: Everyone is excited, seeds arrived in the second week of June and it was a very rainy spring – great conditions for seed germination! The process of fertilizing, seeding & rolling the expansive 1,494.4 acres was spread out over two weeks. Thanks to intermittent rains, we are pleased to report that the crop has started off well.

I refer you to a quote from James in our most recent press release:

Gaia's President James Tworek commented, "Gaia's 2019 crop is planted and off to a great start. We will continue to monitor progress and work with our farmers, contract harvesting, and agronomy teams to optimize timing of harvest, currently estimated to be at the end of September / early October. In the meantime, Gaia's management team is working diligently to firm up contracts with off-take partners to ensure a successful sale and extraction process of the harvest."

Peter Epstein: What are your plans for your maiden hemp crop? Is there demand for 1,500 acres of hemp?

Frederick Pels: Yes, there's tremendous demand! We can either sell the entire crop as biomass on a per acre basis, which would be the easy way to go, or get our biomass processed into higher value CBD extracts. We don't have any extraction equipment, so a third party would have to do it. If the crop develops as expected, we think we could sell it for $3,000-$5,000 per acre.

Screen%20Shot%202019-08-01%20at%2010.06.00%20AM.png

However, if we choose a CBD extraction path, which is more complex and logistically difficult, then we could potentially generate a multiple of the revenue derived from selling the entire crop. Timing is a large part of the issue this year. Next year we fully expect to have an extraction path nailed down.

Peter Epstein: Is there a lot of crop risk between now and harvest?

Frederick Pels: Yes, there is certainly some degree of risk, there always is in agriculture. However, we have a well-respected consulting group managing the grow. And, most of the severe weather is behind us. Frost in late September or early October is a concern, but by then the plants should be fairly robust. We looked into crop insurance, but the first few quotes we received were unattractive. Recently we starting negotiating with a party that we think we could possibly come to terms with.

Peter Epstein: Is Gaia looking to acquire any properties or assets?

Frederick Pels: Yes, absolutely. Interesting opportunities are presented to us almost daily. We see great potential to acquire assets at very attractive valuations in the industrial heartland, where communities are suffering from high unemployment and a low tax base. Having a company like Gaia Grow come into a small town would go a long way towards revitalizing the area with new jobs and investment.

Peter Epstein: Gaia Grow recently raised over $4 million in equity capital. What will the funds be used for?

Frederick Pels: Some of that money was spoken for. We planted hemp seeds on just shy of 1,500 acres over the course of about two weeks and have a consulting group managing the crop. We have operating expenses to pay. But, make no mistake, we want to grow this company. Capital remaining from the $4 million raise will be added to cash flow generated from our crop.

Once we're done with our maiden crop, April, 2020 is right around the corner, time to acquire genetics and get started all over again. Hopefully on a much larger scale.

Peter Epstein: Are you in talks with potential strategic or financial partners?

Frederick Pels: Strategic? Yes, definitely. But, we don't need any financial partners at this time. A lot of eyes are on us, watching this crop, how well it goes for us. As a publicly traded company, we will see all the deal flow we could possibly want. The ability to quickly raise capital is extremely important in the initial years of a market boom (in hemp). We are fully funded for the foreseeable future.

Peter Epstein: Why should investors consider buying shares of Gaia Grow Corp.?

Frederick Pels: We strongly believe that now is the time to be investing in the cultivation of hemp at large commercial-scale. We are looking at opportunities all over North America, but first we need to deliver our first harvest, in about two months. Readers should know that companies can't just buy land and start farming the next day. It takes many months to over a year to get all the permits and approvals, complete surveys and studies, etc. If you miss a growing season, you have no choice but to wait, wait for up to a year, for the next window of opportunity.

We are not waiting! We have a crop in the ground, a fairly large crop of 1,494 acres. If all goes reasonably as planned, it will comfortably fund Gaia Grow Corp. (TSX-V: GAIA) through to bigger and better crops next year. After that? The sky's the limit. We could possibly become vertically integrated with CBD extraction equipment. We could potentially be growing hemp in multiple provinces of Canada and/or states in the U.S. {corporate website}

Peter Epstein: Fredrick, thank you so much for your time. I agree that hemp is a tremendous investment opportunity! I will be watching Gaia Grow closely for news on its maiden hemp crop. Good luck!

Peter Epstein is the founder of Epstein Research. His background is in company and financial analysis. He holds an MBA degree in financial analysis from New York University's Stern School of Business.

[NLINSERT]

Disclosures: The content of this interview is for information only. Readers fully understand and agree that nothing contained herein, written by Peter Epstein of Epstein Research [ER], (together, [ER]) about Gaia Grow, including but not limited to, commentary, opinions, views, assumptions, reported facts, calculations, etc. is not to be considered implicit or explicit investment advice. Nothing contained herein is a recommendation or solicitation to buy or sell any security. [ER] is not responsible under any circumstances for investment actions taken by the reader. [ER] has never been, and is not currently, a registered or licensed financial advisor or broker/dealer, investment advisor, stockbroker, trader, money manager, compliance or legal officer, and does not perform market making activities. [ER] is not directly employed by any company, group, organization, party or person. The shares of Gaia Grows are highly speculative, not suitable for all investors. Readers understand and agree that investments in small cap stocks can result in a 100% loss of invested funds. It is assumed and agreed upon by readers that they will consult with their own licensed or registered financial advisors before making any investment decisions.

Readers understand and agree that they must conduct their own due diligence above and beyond reading this article. While the author believes he’s diligent in screening out companies that, for any reasons, are unattractive investment opportunities, he cannot guarantee that his efforts will (or have been) successful. [ER] is not responsible for any perceived, or actual, errors including, but not limited to, commentary, opinions, views, assumptions, reported facts, financial calculations, etc., or for the completeness of this interview or future content. [ER] is not expected or required to subsequently follow or cover events and news, or write about any particular company. [ER] is not an expert in any company, industry sector or investment topic.

Streetwise Reports Disclosure:
1) Peter Epstein's disclosures are listed above.
2) The following companies mentioned in the article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Graphics provided by the author.




Want to read more about Cannabis and Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe